$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

$ino Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000105572619000012 Filed on March 12, 2019

Income Statement

Concept	2019 Q1	2018 Q1	2017 Q4
Revenue	$2.830M	$1.530M	$8.787M
YoY Change	85.0%	-85.26%	3.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.980M	$9.700M	$8.030M
YoY Change	-28.04%	24.84%	15.21%
% of Gross Profit
Research & Development	$24.39M	$24.58M	$24.64M
YoY Change	-0.76%	0.14%	3.05%
% of Gross Profit
Depreciation & Amortization	$930.9K	$897.7K	$480.0K
YoY Change	3.7%	71.88%	-42.17%
% of Gross Profit
Operating Expenses	$31.36M	$34.28M	$31.68M
YoY Change	-8.49%	6.08%	2.58%
Operating Profit	-$28.54M	-$32.75M	-$22.89M
YoY Change	-12.86%	49.29%	2.35%
Interest Expense	$656.2K	$0.00	$1.380M
YoY Change		-100.0%	-135.66%
% of Operating Profit
Other Income/Expense, Net	-$35.84K
YoY Change
Pretax Income	-$29.35M	-$30.18M	-$21.51M
YoY Change	-2.75%	30.73%	-18.01%
Income Tax	-$62.80K	$2.170M	$0.00
% Of Pretax Income
Net Earnings	-$29.22M	-$32.35M	-$21.51M
YoY Change	-9.68%	40.13%	-18.02%
Net Earnings / Revenue	-1032.52%	-2114.93%	-244.74%
Basic Earnings Per Share	-$0.30	-$0.36	-$0.24
Diluted Earnings Per Share	-$0.30	-$0.36	-$0.24
COMMON SHARES
Basic Shares Outstanding	97.64M shares	90.45M shares	90.30M shares
Diluted Shares Outstanding		90.45M shares

Balance Sheet

Concept	2019 Q1	2018 Q1	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$128.0M	$116.1M	$127.4M
YoY Change	10.27%	29.4%	21.56%
Cash & Equivalents	$20.78M	$37.51M	$23.79M
Short-Term Investments	$107.2M	$78.57M	$103.6M
Other Short-Term Assets	$2.800M	$3.700M	$4.400M
YoY Change	-24.32%	-38.33%	33.33%
Inventory
Prepaid Expenses
Receivables	$2.783M	$5.148M	$6.003M
Other Receivables	$1.300M	$2.300M	$500.0K
Total Short-Term Assets	$134.9M	$123.8M	$138.4M
YoY Change	8.94%	15.97%	11.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.19M	$17.49M	$18.32M
YoY Change	-13.15%	78.37%	102.98%
Goodwill	$10.51M	$10.51M	$10.51M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$4.494M	$5.606M	$6.010M
YoY Change	-19.84%	-22.38%	-21.22%
Long-Term Investments	$8.700M	$13.80M	$11.40M
YoY Change	-36.96%	-21.14%	-42.42%
Other Assets	$2.981M	$2.449M	$2.639M
YoY Change	21.75%	60.55%	24.9%
Total Long-Term Assets	$56.26M	$49.83M	$48.88M
YoY Change	12.91%	7.08%	-0.47%
TOTAL ASSETS
Total Short-Term Assets	$134.9M	$123.8M	$138.4M
Total Long-Term Assets	$56.26M	$49.83M	$48.88M
Total Assets	$191.2M	$173.7M	$187.2M
YoY Change	10.08%	13.27%	7.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.00M	$17.10M	$24.20M
YoY Change	-0.58%	14.0%	16.91%
Accrued Expenses	$7.159M	$8.429M	$8.612M
YoY Change	-15.06%	42.62%	35.23%
Deferred Revenue	$110.7K		$1.175M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.42M	$51.38M	$35.41M
YoY Change	-46.64%	28.43%	-19.21%
LONG-TERM LIABILITIES
Long-Term Debt	$60.60M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$64.26K	$9.200M	$0.00
YoY Change	-99.3%	27.78%	-100.0%
Total Long-Term Liabilities	$64.26K	$9.200M	$0.00
YoY Change	-99.3%	27.78%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.42M	$51.38M	$35.41M
Total Long-Term Liabilities	$64.26K	$9.200M	$0.00
Total Liabilities	$110.2M	$60.57M	$44.75M
YoY Change	81.94%	27.87%	-11.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$649.6M	-$523.1M	-$523.4M
YoY Change	24.19%	14.16%	20.36%
Common Stock	$97.93K	$90.71K	$90.36K
YoY Change	7.97%	21.54%	22.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$77.91M	$113.0M	$142.4M
YoY Change
Total Liabilities & Shareholders Equity	$191.2M	$173.7M	$187.2M
YoY Change	10.08%	13.27%	7.79%

Cashflow Statement

Concept	2019 Q1	2018 Q1	2017 Q4
OPERATING ACTIVITIES
Net Income	-$29.22M	-$32.35M	-$21.51M
YoY Change	-9.68%	40.13%	-18.02%
Depreciation, Depletion And Amortization	$930.9K	$897.7K	$480.0K
YoY Change	3.7%	71.88%	-42.17%
Cash From Operating Activities	-$32.45M	-$12.58M	-$13.95M
YoY Change	158.08%	-17.42%	-6.44%
INVESTING ACTIVITIES
Capital Expenditures	$658.7K	$1.153M	-$870.0K
YoY Change	-42.89%	46.15%	1142.86%
Acquisitions
YoY Change
Other Investing Activities	-$48.68M	$27.96M	$15.46M
YoY Change	-274.11%	47.47%	54.91%
Cash From Investing Activities	-$49.34M	$26.80M	$14.58M
YoY Change	-284.07%	47.54%	46.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$907.3K	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$78.88M	-$506.4K	-120.0K
YoY Change	-15675.93%	-161.28%	-113.79%
NET CHANGE
Cash From Operating Activities	-$32.45M	-$12.58M	-13.95M
Cash From Investing Activities	-$49.34M	$26.80M	14.58M
Cash From Financing Activities	$78.88M	-$506.4K	-120.0K
Net Change In Cash	-$2.914M	$13.72M	510.0K
YoY Change	-121.24%	264.3%	-112.38%
FREE CASH FLOW
Cash From Operating Activities	-$32.45M	-$12.58M	-$13.95M
Capital Expenditures	$658.7K	$1.153M	-$870.0K
Free Cash Flow	-$33.11M	-$13.73M	-$13.08M
YoY Change	141.2%	-14.29%	-11.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001055726
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	97636364	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	335998116	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	INOVIO PHARMACEUTICALS, INC.
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017Q4	ino	Accrued Subcontract Expenses AccruedSubcontractExpenses	3746937	USD
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018Q4	ino	Accrued Subcontract Expenses AccruedSubcontractExpenses	83812	USD
CY2016	ino	Adjustment For Change In Fair Value Of Warrant Liability AdjustmentForChangeInFairValueOfWarrantLiability	0	USD
CY2017	ino	Adjustment For Change In Fair Value Of Warrant Liability AdjustmentForChangeInFairValueOfWarrantLiability	-806819	USD
CY2018	ino	Adjustment For Change In Fair Value Of Warrant Liability AdjustmentForChangeInFairValueOfWarrantLiability	0	USD
CY2016	ino	Cashless Exerciseof Warrants Value CashlessExerciseofWarrantsValue	0	USD
CY2016	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	127554	USD
CY2017Q1	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	116477	USD
CY2017Q2	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-312500	USD
CY2017Q3	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	423296	USD
CY2017Q4	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	579546	USD
CY2017	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	806819	USD
CY2018Q1	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	-127841	USD
CY2018Q2	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	259971	USD
CY2018Q3	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	228665	USD
CY2018Q4	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	0	USD
CY2018	ino	Change In Fair Value Of Common Stock Warrants ChangeInFairValueOfCommonStockWarrants	360795	USD
CY2016	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	-127554	USD
CY2017	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	-806819	USD
CY2018	ino	Change In Value Of Common Stock Warrants ChangeInValueOfCommonStockWarrants	-360795	USD
CY2016	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	1110787	USD
CY2017Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-1608817	USD
CY2017Q2	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	169096	USD
CY2017Q3	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-5835741	USD
CY2017Q4	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	292798	USD
CY2017	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-6982664	USD
CY2018Q1	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	2380423	USD
CY2018Q2	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-2092608	USD
CY2018Q3	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	1017359	USD
CY2018Q4	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-3293741	USD
CY2018	ino	Change In Value Of Investments In Affiliated Company ChangeInValueOfInvestmentsInAffiliatedCompany	-1988567	USD
CY2016	ino	Common Stock Issued For Intangible And Other Assets CommonStockIssuedForIntangibleAndOtherAssets	4300000	USD
CY2017	ino	Common Stock Issued For Intangible And Other Assets CommonStockIssuedForIntangibleAndOtherAssets	0	USD
CY2018	ino	Common Stock Issued For Intangible And Other Assets CommonStockIssuedForIntangibleAndOtherAssets	0	USD
CY2016	ino	Comprehensive Income Loss Tax Expense Benefit ComprehensiveIncomeLossTaxExpenseBenefit	0	USD
CY2017	ino	Comprehensive Income Loss Tax Expense Benefit ComprehensiveIncomeLossTaxExpenseBenefit	0	USD
CY2018	ino	Comprehensive Income Loss Tax Expense Benefit ComprehensiveIncomeLossTaxExpenseBenefit	2170000	USD
CY2018	ino	Convertible Preferred Stock Shares Issued Upon Conversion Conversion Price Per Share ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare	27.20
CY2018	ino	Convertible Preferred Stock Threshold Consecutive Trading Days ConvertiblePreferredStockThresholdConsecutiveTradingDays	30	day
CY2018	ino	Convertible Preferred Stock Threshold Trading Days ConvertiblePreferredStockThresholdTradingDays	20	day
CY2017Q4	ino	Deferred Grant Funding Current DeferredGrantFundingCurrent	0	USD
CY2018Q4	ino	Deferred Grant Funding Current DeferredGrantFundingCurrent	4165848	USD
CY2017Q4	ino	Deferred Grant Funding From Affiliate Current DeferredGrantFundingFromAffiliateCurrent	0	USD
CY2018Q4	ino	Deferred Grant Funding From Affiliate Current DeferredGrantFundingFromAffiliateCurrent	27083	USD
CY2017Q4	ino	Deferred Revenue From Affiliated Entity Current DeferredRevenueFromAffiliatedEntityCurrent	174110	USD
CY2018Q4	ino	Deferred Revenue From Affiliated Entity Current DeferredRevenueFromAffiliatedEntityCurrent	33575	USD
CY2017Q4	ino	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	858000	USD
CY2018Q4	ino	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	912000	USD
CY2016	ino	Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits	4269000	USD
CY2017	ino	Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits	454000	USD
CY2018	ino	Effective Income Tax Reconciliation Expired Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits	2176000	USD
CY2016	ino	Effective Income Tax Reconciliation Foreign Withholding Taxes Amount EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount	0	USD
CY2017	ino	Effective Income Tax Reconciliation Foreign Withholding Taxes Amount EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount	0	USD
CY2018	ino	Effective Income Tax Reconciliation Foreign Withholding Taxes Amount EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount	2170000	USD
CY2016	ino	Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits	-6456000	USD
CY2017	ino	Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits	-165000	USD
CY2018	ino	Effective Income Tax Reconciliation Limited Net Operating Lossesand Credits EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits	-2176000	USD
CY2017Q4	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	35231244	USD
CY2018Q4	ino	Goodwill And Intangible Assets Gross GoodwillAndIntangibleAssetsGross	35231244	USD
CY2017Q4	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	16523100	USD
CY2018Q4	ino	Goodwill And Intangible Assets Net GoodwillAndIntangibleAssetsNet	15273516	USD
CY2018	ino	Grant Proceeds Received GrantProceedsReceived	9500000	USD
CY2016	ino	Impairment Of Long Term Investments ImpairmentOfLongTermInvestments	139249	USD
CY2017	ino	Impairment Of Long Term Investments ImpairmentOfLongTermInvestments	215423	USD
CY2018	ino	Impairment Of Long Term Investments ImpairmentOfLongTermInvestments	1342005	USD
CY2016	ino	Income Tax Reconciliation Fair Value Warrant IncomeTaxReconciliationFairValueWarrant	-47000	USD
CY2017	ino	Income Tax Reconciliation Fair Value Warrant IncomeTaxReconciliationFairValueWarrant	-282000	USD
CY2018	ino	Income Tax Reconciliation Fair Value Warrant IncomeTaxReconciliationFairValueWarrant	-76000	USD
CY2016	ino	Income Tax Reconciliation Statute Limitations IncomeTaxReconciliationStatuteLimitations	-3117000	USD
CY2017	ino	Income Tax Reconciliation Statute Limitations IncomeTaxReconciliationStatuteLimitations	-3456000	USD
CY2018	ino	Income Tax Reconciliation Statute Limitations IncomeTaxReconciliationStatuteLimitations	-3170000	USD
CY2016	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-687827	USD
CY2017	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-319876	USD
CY2018	ino	Increase Decrease In Deferred Revenue From Related Parties IncreaseDecreaseInDeferredRevenueFromRelatedParties	-140535	USD
CY2016	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	901772	USD
CY2017	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	333583	USD
CY2018	ino	Increase Decrease In Prepaid Expenses And Other Current Assets From Affiliated Entity IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	-725202	USD
CY2016	ino	Increase Decreasein Deferred Grant Funding Current IncreaseDecreaseinDeferredGrantFundingCurrent	0	USD
CY2017	ino	Increase Decreasein Deferred Grant Funding Current IncreaseDecreaseinDeferredGrantFundingCurrent	0	USD
CY2018	ino	Increase Decreasein Deferred Grant Funding Current IncreaseDecreaseinDeferredGrantFundingCurrent	4165848	USD
CY2016	ino	Increase Decreasein Deferred Grant Funding From Affiliate Current IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent	0	USD
CY2017	ino	Increase Decreasein Deferred Grant Funding From Affiliate Current IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent	0	USD
CY2018	ino	Increase Decreasein Deferred Grant Funding From Affiliate Current IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent	27083	USD
CY2016	ino	Issuance Of Common Stock For Cash Financing Costs IssuanceOfCommonStockForCashFinancingCosts	128000	USD
CY2017	ino	Issuance Of Common Stock For Cash Financing Costs IssuanceOfCommonStockForCashFinancingCosts	4900000	USD
CY2018	ino	Issuance Of Common Stock For Cash Financing Costs IssuanceOfCommonStockForCashFinancingCosts	0	USD
CY2016	ino	Other Comprehensive Income Loss Unrealized Gain Loss On Investment In Affiliated Entity Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax	-1268404	USD
CY2017	ino	Other Comprehensive Income Loss Unrealized Gain Loss On Investment In Affiliated Entity Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax	-1452431	USD
CY2018	ino	Other Comprehensive Income Loss Unrealized Gain Loss On Investment In Affiliated Entity Net Of Tax OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax	0	USD
CY2018	ino	Preferred Stock Conversion Daily Market Price Triggering Mandatory Conversion PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion	72.00
CY2017Q4	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	1846007	USD
CY2018Q4	ino	Prepaid Expenses And Other Current Assets From Affiliated Entity PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity	1120805	USD
CY2016	ino	Proceedsfrom Stock Optionand Warrant Exercises ProceedsfromStockOptionandWarrantExercises	1640740	USD
CY2018	ino	Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm	P5Y9M0D
CY2018	ino	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue	1600000	USD
CY2017	ino	Proceedsfrom Stock Optionand Warrant Exercises ProceedsfromStockOptionandWarrantExercises	1342250	USD
CY2018	ino	Proceedsfrom Stock Optionand Warrant Exercises ProceedsfromStockOptionandWarrantExercises	1809526	USD
CY2018Q4	ino	Sharebased Compensation Arrangementby Sharebased Payment Award Options Expectedto Vest Outstanding Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber	8752677	shares
CY2018Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	10043816	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	23134733	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	7564830	USD
CY2017	ino	Stock Issued During Period Shares Warrants Exercised In Period StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod	0	shares
CY2018	ino	Stock Issued During Period Shares Warrants Exercised In Period StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod	284091	shares
CY2018Q4	ino	Tax Benefits Expired TaxBenefitsExpired	11200000	USD
CY2018	ino	Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Decrease In Deferred Tax Asset TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateDecreaseInDeferredTaxAsset	50000000	USD
CY2018	ino	Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Decrease In Valuation Allowance TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateDecreaseInValuationAllowance	50200000	USD
CY2018	ino	Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Provisional Income Tax Expense Benefit TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateProvisionalIncomeTaxExpenseBenefit	-200000	USD
CY2018Q4	ino	Working Capital WorkingCapital	52500000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23278798	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23134733	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	23278798	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6003205	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3316361	USD
CY2017Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	486619	USD
CY2018Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	738583	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8611892	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5671764	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7997152	USD
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	9466821	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7106557	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9999919	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-117005	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-528867	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-348371	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	665775504	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	707794215	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10479135	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13070962	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10654622	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1377466	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1618665	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1249584	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7897564	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8937494	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10449150	shares
CY2017Q4	us-gaap	Assets Assets	187239270	USD
CY2018Q4	us-gaap	Assets Assets	131113265	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	138362160	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	87814824	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	528736	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	58067588	USD
CY2015Q2	us-gaap	Available For Sale Equity Securities Amortized Cost Basis AvailableForSaleEquitySecuritiesAmortizedCostBasis	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2370208	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	392571	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	103986286	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	105963923	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23786579	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23693633	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-38496221	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4650107	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	57538852	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	164923	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	851204	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	694472	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57632693	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19136472	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-92946	USD
CY2018Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	81200000	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	284091	shares
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90357644	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97225810	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90357644	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97225810	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	90358	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	97226	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-75120710	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-89650745	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-97148326	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1175353	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	223577	USD
CY2017Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	215853	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	150793	USD
CY2017	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	14800000	USD
CY2018	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1300000	USD
CY2017Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2170000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	193000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7408000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1952000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2170000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	10	investment
CY2018Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	14	investment
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	24766	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	24766	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	877535	USD
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1065387	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9104416	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8518207	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	297000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	985000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	95991000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	116250000	USD
CY2017Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	8546000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1243000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	71665000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	89399000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1906000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2693000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	7531000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	9432000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3091000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3408000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	2097000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	2013000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94039000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	115007000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	24000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	24000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	124000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	142000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	422000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Investment In Noncontrolled Affiliates DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates	4000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1430000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1121000	USD
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	496000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	822000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1200000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.5
CY2016	us-gaap	Depreciation Depreciation	1708498	USD
CY2017	us-gaap	Depreciation Depreciation	1850376	USD
CY2018	us-gaap	Depreciation Depreciation	3747183	USD
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	926943	USD
CY2018Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	977792	USD
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5900000	USD
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5200000	USD
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M15D
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M31D
CY2017Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2325079	USD
CY2018Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	3023987	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-134000	USD
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-807000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-361000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18708144	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19957728	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1857778	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1066251	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-14529	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	275803	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	492818	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	520414	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	547081	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24717873	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	24717873	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6009729	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4760145	USD
CY2016	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	USD
CY2017Q1	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2017Q2	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2017Q3	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2017Q4	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	USD
CY2017	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	USD
CY2018	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23892263	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7767589	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6169106	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6319775	USD
CY2017Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8033899	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28290369	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9698015	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7189310	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6791693	USD
CY2018Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5636141	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29315159	USD
CY2017Q4	us-gaap	Goodwill Goodwill	10513371	USD
CY2018Q4	us-gaap	Goodwill Goodwill	10513371	USD
CY2017Q4	us-gaap	Goodwill Gross GoodwillGross	10513371	USD
CY2018Q4	us-gaap	Goodwill Gross GoodwillGross	10513371	USD
CY2016	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-73740339	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88205772	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30181017	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6639125	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25015672	USD
CY2018Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32962205	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94798019	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2169811	USD
CY2018Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2170000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2169811	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2200000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29678000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-20965000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20898000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-495000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	50019000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-25809000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-30872000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19908000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	113000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2332000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1094000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	501000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2093000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-102000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4000	USD
CY2016	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1367000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	846000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1268000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6367965	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2829807	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	550407	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	907532	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-145636	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	50849	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8521899	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9818306	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2686844	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	714908	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-261736	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	251964	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3767906	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2243503	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2940128	USD
CY2016	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1527686	USD
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13689322	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1016836	USD
CY2016	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	849	USD
CY2017	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	150027	USD
CY2018	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1442314	USD
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	526207	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	30644	USD
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	87333	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	831802	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	851847	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1194316	USD
CY2016	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	140529	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6009729	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4760145	USD
CY2016	us-gaap	Interest And Other Income InterestAndOtherIncome	1257257	USD
CY2017Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	340341	USD
CY2017Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	300021	USD
CY2017Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	463346	USD
CY2017Q4	us-gaap	Interest And Other Income InterestAndOtherIncome	509266	USD
CY2017	us-gaap	Interest And Other Income InterestAndOtherIncome	1612974	USD
CY2018Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	312523	USD
CY2018Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	396681	USD
CY2018Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	380987	USD
CY2018Q4	us-gaap	Interest And Other Income InterestAndOtherIncome	-169300	USD
CY2018	us-gaap	Interest And Other Income InterestAndOtherIncome	920891	USD
CY2016	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	266290	USD
CY2017	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	319845	USD
CY2018	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	72561	USD
CY2017Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	9069401	USD
CY2018Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	6381926	USD
CY2016Q4	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	523856	USD
CY2017Q4	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	0	USD
CY2018Q4	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	0	USD
CY2017Q4	us-gaap	Liabilities Liabilities	44750461	USD
CY2018Q4	us-gaap	Liabilities Liabilities	44080858	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	187239270	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	131113265	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35405426	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16271889	USD
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	32001788	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	124573035	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35299759	USD
CY2018Q4	us-gaap	Long Term Investments LongTermInvestments	9400000	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	96269	USD
CY2018Q4	us-gaap	Minority Interest MinorityInterest	96269	USD
CY2016	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	149559	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7786942	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95690172	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31037302	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27831144	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	42419908	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62555052	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63208921	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73550156	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-73740339	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-88205772	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-96967830	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-73740339	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-89012591	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-96967830	USD
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016	us-gaap	Operating Expenses OperatingExpenses	111604298	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	32310093	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	30047857	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	31830014	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	31675023	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	125862987	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	34275766	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	29651930	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	28643551	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-76235937	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-21933908	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9635733	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-29185471	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-22887789	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-83642901	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-32746122	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5203169	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-26642683	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-29499164	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-94091138	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	35653000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	3756000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	4023000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4052000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	3979000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3891000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	15952000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1600000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2400000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3200000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	3969879	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	3540284	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2639354	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2669998	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-111967	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7458	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-180496	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	87333	USD
CY2017	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2018	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2017	us-gaap	Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings	215000	USD
CY2018	us-gaap	Other Than Temporary Impairment Loss Debt Securities Portion Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesPortionRecognizedInEarnings	1300000	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1200000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2738470	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10293902	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2085022	USD
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	57317671	USD
CY2017	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	95700144	USD
CY2018	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	88155046	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	23	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	23	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	23	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	23	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2600906	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1406590	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6295761	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	94347922	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29227776	USD
CY2016	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-149559	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2016	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	1000000	USD
CY2017	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	1000000	USD
CY2018	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	0	USD
CY2016	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	76528030	USD
CY2017	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	77162902	USD
CY2018	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	132659976	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1800000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2300000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1500000	USD
CY2018Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	902000	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	902000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	-73740339	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	-23085907	USD
CY2017Q2	us-gaap	Profit Loss ProfitLoss	-9479116	USD
CY2017Q3	us-gaap	Profit Loss ProfitLoss	-34134570	USD
CY2017Q4	us-gaap	Profit Loss ProfitLoss	-21506179	USD
CY2017	us-gaap	Profit Loss ProfitLoss	-88205772	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-32350828	USD
CY2018Q2	us-gaap	Profit Loss ProfitLoss	-6639125	USD
CY2018Q3	us-gaap	Profit Loss ProfitLoss	-25015672	USD
CY2018Q4	us-gaap	Profit Loss ProfitLoss	-32962205	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-96967830	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25426733	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25948933	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18320176	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15949014	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	88712035	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24542504	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23878751	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25510239	USD
CY2017Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24641124	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	98572618	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24577751	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22462620	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21851858	USD
CY2018Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26365647	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	95257876	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-523356317	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-620426436	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-523124951	USD
CY2016	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	35368361	USD
CY2017Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10376185	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20412124	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2644543	USD
CY2017Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8787234	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	42220086	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1529644	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24448761	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2000868	USD
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2502624	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30481897	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	10479135	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	13070962	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	10654622	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	284091	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	519000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	910000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	69570	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	200501	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	119091	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	646366	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.83
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2176935	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.59
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.33
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.86
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7694870	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8752677	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.77
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.35
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.21
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.01
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	9.67
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.17
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.32
CY2018Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	6154495	shares
CY2018Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	8752677	shares
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1600000	USD
CY2018Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	6.78
CY2018Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	6.35
CY2018	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y7M31D
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	103638844	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	57538852	USD
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	472762	shares
CY2016	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	4300000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6295761	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	94347922	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	7100000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	8300000	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	360795	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	361000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	86936138	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	175933053	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	123378420	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	142488809	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	87032407	USD
CY2016	us-gaap	Straight Line Rent StraightLineRent	16728	USD
CY2018Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73214766	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81918022	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92539997	shares
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	29227776	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1640740	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1342250	USD
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1809526	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	142392540	USD
CY2017	us-gaap	Straight Line Rent StraightLineRent	-3608881	USD
CY2018	us-gaap	Straight Line Rent StraightLineRent	398357	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5455000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6855000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6855000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8313000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8313000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9632000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	74000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1183000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1532000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1319000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	217000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	5700000	USD
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73214766	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81777493	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92539997	shares
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments, that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</font></div></div>
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio Pharmaceuticals, Inc. (the “Company” or “Inovio”), is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines that transform the treatment and prevention of cancers and infectious diseases. The Company's DNA-based immunotherapies and vaccines, in combination with its proprietary, efficacy-enabling delivery devices, are intended to generate robust immune responses, in particular functional CD8+ killer T cells and antibodies, to fight target diseases.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio’s synthetic products are based on its SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> immunotherapy design. The Company and its collaborators are currently conducting or planning clinical programs of its proprietary SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> immunotherapies for HPV-caused pre-cancers, including cervical, vulvar, and anal dysplasia; HPV-caused cancers, including head & neck, cervical, anal, penile, vulvar, and vaginal; bladder cancer; glioblastoma multiforme ("GBM"); hepatitis B virus; hepatitis C virus; HIV; Ebola; Middle East Respiratory Syndrome, or MERS; Lassa fever; and Zika virus. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's partners and collaborators include MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"), The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc. ("GeneOne"), ApolloBio Corporation, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., Drexel University, National Institute of Allergy and Infectious Diseases (“NIAID”), United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency (“DARPA”), Parker Institute for Cancer Immunotherapy, and Coalition for Epidemic Preparedness Innovations (“CEPI”).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001055726-19-000012-index-headers.html	Edgar Link	pending
0001055726-19-000012-index.html	Edgar Link	pending
0001055726-19-000012.txt	Edgar Link	pending
0001055726-19-000012-xbrl.zip	Edgar Link	pending
a10kgraph.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
grapha07.jpg	Edgar Link	pending
ino-12312018x10k.htm	Edgar Link	pending
ino-12312018x10kex1043.htm	Edgar Link	pending
ino-12312018x10kex211.htm	Edgar Link	pending
ino-12312018x10kex231.htm	Edgar Link	pending
ino-12312018x10kex311.htm	Edgar Link	pending
ino-12312018x10kex312.htm	Edgar Link	pending
ino-12312018x10kex321.htm	Edgar Link	pending
ino-20181231.xml	Edgar Link	completed
ino-20181231.xsd	Edgar Link	pending
ino-20181231_cal.xml	Edgar Link	unprocessable
ino-20181231_def.xml	Edgar Link	unprocessable
ino-20181231_lab.xml	Edgar Link	unprocessable
ino-20181231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino

2019 Q1 Form 10-K Financial Statement

#000105572619000012 Filed on March 12, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO INOVIO PHARMACEUTICALS, INC. Stock $ino

2019 Q1 Form 10-K Financial Statement

#000105572619000012 Filed on March 12, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INO
INOVIO PHARMACEUTICALS, INC. Stock $ino